Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 11, 2011, Pages 955-965

  Manuel, Oriol ^a   Perrottet, Nancy ^a   Pascual, Manuel ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

antiviral prophylaxis; cell mediated immunity; indirect effects; low dose valganciclovir; pre emptive approach

Indexed keywords

GANCICLOVIR; PLACEBO; VALGANCICLOVIR;

AREA UNDER THE CURVE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; GRAFT RECIPIENT; HEMATOLOGIC DISEASE; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGICAL MONITORING; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; LEUKOPENIA; LOW DRUG DOSE; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; ORGAN TRANSPLANTATION; REVIEW; THERAPY DELAY; TREATMENT DURATION; TREATMENT OUTCOME; VIRAL CLEARANCE; VIREMIA; VIRUS LOAD;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; CYTOKINES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG DOSAGE CALCULATIONS; GANCICLOVIR; HUMANS; IMMUNITY, CELLULAR; IMMUNOCOMPROMISED HOST; ORGAN TRANSPLANTATION; PRACTICE GUIDELINES AS TOPIC; PRODRUGS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TRANSPLANTATION CONDITIONING; VIRAL LOAD; VIRUS REPLICATION;

EID: 80155177971     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.116     Document Type: Review

References (101)

1. Fishman JA. Infection in solid-organ transplant recipients. N. Engl. J. Med. 357(25), 2601-2614 (2007).
2. Glenn J. Cytomegalovirus infections following renal transplantation. Rev. Infect. Dis. 3(6), 1151-1178 (1981).
3. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am. J. Transplant. 6(2), 262-274 (2006).
4. Manuel O, Meylan PR, Rotman S, Fontana M, Moradpour D, Pascual M. Oral valganciclovir for cytomegalovirus colitis after liver transplantation. Transplantation 83(2), 239-240 (2007).
5. Lautenschlager I, Halme L, Hockerstedt K, Krogerus L, Taskinen E. Cytomegalovirus infection of the liver transplant: virological, histological, immunological, and clinical observations. Transpl. Infect. Dis. 8(1), 21-30 (2006).
6. Duncan SR, Paradis IL, Yousem SA et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am. Rev. Respir. Dis. 146(6), 1419-1425 (1992).
7. Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant. 4(4), 611-620 (2004).
8. Humar A, Lebranchu Y, Vincenti F et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am. J. Transplant. 10(5), 1228-1237 (2010).
9. Freeman RB Jr. The 'indirect' effects of cytomegalovirus infection. Am. J. Transplant. 9(11), 2453-2458 (2009).
10. Craigen JL, Yong KL, Jordan NJ et al. Human cytomegalovirus infection up-regulates interleukin-8 gene expression and stimulates neutrophil transendothelial migration. Immunology 92(1), 138-145 (1997).
11. Helantera I, Loginov R, Koskinen P, Tornroth T, Gronhagen-Riska C, Lautenschlager I. Persistent cytomegalovirus infection is associated with increased expression of TGF-β1, PDGF-AA and ICAM-1 and arterial intimal thickening in kidney allografts. Nephrol. Dial. Transplant. 20(4), 790-796 (2005).
12. Sester U, Presser D, Dirks J, Gartner BC, Kohler H, Sester M. PD-1 expression and IL-2 loss of cytomegalovirus- specific T cells correlates with viremia and reversible functional anergy. Am. J. Transplant. 8(7), 1486-1497 (2008).
13. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 261(24), 3561-3566 (1989).
14. Pouteil-Noble C, Ecochard R, Landrivon G et al. Cytomegalovirus infection - an etiological factor for rejection? A prospective study in 242 renal transplant patients. Transplantation 55(4), 851-857 (1993).
15. Bando K, Paradis IL, Similo S et al. Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management. J. Thorac. Cardiovasc. Surg. 110(1), 4-13 (1995).
16. Helantera I, Koskinen P, Finne P et al. Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival. Transpl. Int. 19(11), 893-900 (2006).
17. Opelz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am. J. Transplant. 4(6), 928-936 (2004).
18. Falagas ME, Snydman DR, Griffith J, Werner BG. Exposure to cytomegalovirus from the donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. Clin. Infect. Dis. 23(3), 468-474 (1996).
19. George MJ, Snydman DR, Werner BG et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am. J. Med. 103(2), 106-113 (1997).
20. Humar A, Malkan G, Moussa G, Greig P, Levy G, Mazzulli T. Human herpesvirus-6 is associated with cytomegalovirus reactivation in liver transplant recipients. J. Infect. Dis. 181(4), 1450-1453 (2000).
21. Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect. Dis. 4(12), 725-738 (2004).
22. Leung Ki EL, Venetz JP, Meylan P, Lamoth F, Ruiz J, Pascual M. Cytomegalovirus infection and new-onset post-transplant diabetes mellitus. Clin. Transplant. 22(2), 245-249 (2008).
23. Walker RC, Marshall WF, Strickler JG et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin. Infect. Dis. 20(5), 1346-1353 (1995).
24. Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am. J. Transplant. 9(Suppl. 4), S78-S86 (2009).
25. Limaye AP, Bakthavatsalam R, Kim HW et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 78(9), 1390-1396 (2004).
26. Limaye AP, Bakthavatsalam R, Kim HW et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 81(12), 1645-1652 (2006).
27. Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N. Engl. J. Med. 340(19), 1462-1470 (1999).
28. Manuel O, Pascual M, Trendelenburg M, Meylan PR. Association between mannose-binding lectin deficiency and cytomegalovirus infection after kidney transplantation. Transplantation 83(3), 359-362 (2007).
29. Cervera C, Lozano F, Saval N et al. The influence of innate immunity gene receptors polymorphisms in renal transplant infections. Transplantation 83(11), 1493-1500 (2007).
30. Razonable RR, Rivero A, Rodriguez A et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J. Infect. Dis. 184(11), 1461-1464 (2001).
31. Brennan DC, Daller JA, Lake KD, Cibrik D, Del CD. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N. Engl. J. Med. 355(19), 1967-1977 (2006).
32. Eisen HJ, Kobashigawa J, Keogh A et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J. Heart Lung Transplant. 24(5), 517-525 (2005).
33. San JR, Aguado JM, Lumbreras C et al. Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin. Infect. Dis. 47(7), 875-882 (2008).
34. Scalzo AA, Corbett AJ, Rawlinson WD, Scott GM, Degli-Esposti MA. The interplay between host and viral factors in shaping the outcome of cytomegalovirus infection. Immunol. Cell Biol. 85(1), 46-54 (2007).
35. Chou SW, Dennison KM. Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes. J. Infect. Dis. 163(6), 1229-1234 (1991).
36. Navarro D, Paz P, Tugizov S, Topp K, La VJ, Pereira L. Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, transmission of infection from cell to cell, and fusion of infected cells. Virology 197(1), 143-158 (1993).
37. Manuel O, Asberg A, Pang X et al. Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease. Clin. Infect. Dis. 49(8), 1160-1166 (2009).
38. Gorzer I, Guelly C, Trajanoski S, Puchhammer-Stockl E. Deep sequencing reveals highly complex dynamics of human cytomegalovirus genotypes in transplant patients over time. J. Virol. 84(14), 7195-7203 (2010).
39. Fishman JA, Emery V, Freeman R et al. Cytomegalovirus in transplantation - challenging the status quo. Clin. Transplant. 21(2), 149-158 (2007).
40. Gane E, Saliba F, Valdecasas GJ et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 350(9093), 1729-1733 (1997).
41. Manuel O, Venetz JP, Fellay J et al. Efficacy and safety of universal valganciclovir prophylaxis combined with a tacrolimus/mycophenolate-based regimen in kidney transplantation. Swiss Med. Wkly 137(47-48), 669-676 (2007).
42. Meylan PR, Pascual M. Preemptive versus prophylactic approaches in the management of cytomegalovirus disease in solid organ transplant recipients: what we know and what we do not know. Clin. Infect. Dis. 43(7), 881-883 (2006).
43. Hodson EM, Jones CA, Webster AC et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 365(9477), 2105-2115 (2005).
44. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann. Intern. Med. 143(12), 870-880 (2005).
45. Meylan PR, Manuel O. Late-onset cytomegalovirus disease in patients with solid organ transplant. Curr. Opin. Infect. Dis. 20(4), 412-418 (2007).
46. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am. J. Transplant. 8(5), 975-983 (2008).
47. Danziger-Isakov L, Mark BG. Hematologic complications of anti-CMV therapy in solid organ transplant recipients. Clin. Transplant. 23(3), 295-304 (2009).
48. Zamora MR, Nicolls MR, Hodges TN et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am. J. Transplant. 4(10), 1635-1642 (2004).
49. Benmarzouk-Hidalgo OJ, Cisneros JM, Cordero E et al. Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment. Transplantation 91(8), 927-933 (2011).
50. Diaz-Pedroche C, Lumbreras C, San JR et al. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients. Transplantation 82(1), 30-35 (2006).
51. Muheim C, Vogel G, Seydoux C et al. Determinants of protracted cytomegalovirus infection in solid-organ transplant patients. Transplantation 74(2), 226-236 (2002).
52. Singh N, Wannstedt C, Keyes L et al. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts. Liver Transpl. 14(2), 240-244 (2008).
53. Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am. J. Transplant. 8(1), 69-77 (2008).
54. Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin. Infect. Dis. 43(7), 869-880 (2006).
55. Kotton CN, Kumar D, Caliendo AM et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89(7), 779-795 (2010).
56. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am. J. Transplant. 9(Suppl. 3), S1-S155 (2009).
57. Sugawara M, Huang W, Fei YJ, Leibach FH, Ganapathy V, Ganapathy ME. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J. Pharm. Sci. 89(6), 781-789 (2000).
58. Lai L, Xu Z, Zhou J, Lee KD, Amidon GL. Molecular basis of prodrug activation by human valacyclovirase, an a-amino acid ester hydrolase. J. Biol. Chem. 283(14), 9318-9327 (2008).
59. Caldes A, Colom H, Armendariz Y et al. Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. Antimicrob. Agents Chemother. 53(11), 4816-4824 (2009).
60. Caldes A, Gil-Vernet S, Armendariz Y et al. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics. Transpl. Infect. Dis. 12(3), 204-212 (2010).
61. Pescovitz MD, Rabkin J, Merion RM et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob. Agents Chemother. 44(10), 2811-2815 (2000).
62. Perrottet N, Decosterd LA, Meylan P, Pascual M, Biollaz J, Buclin T. Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. Clin. Pharmacokinet. 48(6), 399-418 (2009).
63. Pescovitz MD, Jain A, Robson R, Mulgaonkar S, Freeman R, Bouw MR. Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation. Transplant. Proc. 39(10), 3111-3116 (2007).
64. Welker H, Farhan M, Humar A, Washington C. Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days. Transplantation 90(12), 1414-1419 (2010).
65. Wiltshire H, Hirankarn S, Farrell C et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin. Pharmacokinet. 44(5), 495-507 (2005).
66. Perrottet N, Csajka C, Pascual M et al. Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir. Antimicrob. Agents Chemother. 53(7), 3017-3023 (2009).
67. Cvetkovic RS, Wellington K. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs 65(6), 859-878 (2005).
68. Matthews T, Boehme R. Antiviral activity and mechanism of action of ganciclovir. Rev. Infect. Dis. 10(Suppl. 3), S490-S494 (1988).
69. Wiltshire H, Paya CV, Pescovitz MD et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 79(11), 1477-1483 (2005).
70. Perrottet N, Manuel O, Lamoth F et al. Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R-transplant recipients. BMC Infect. Dis. 10, 2 (2010).
71. Kalil AC, Freifeld AG, Lyden ER, Stoner JA. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. PLoS One 4(5), e5512 (2009).
72. Levitsky J, Singh N, Wagener MM, Stosor V, Abecassis M, Ison MG. A survey of CMV prevention strategies after liver transplantation. Am. J. Transplant. 8(1), 158-161 (2008).
73. Humar A, Limaye AP, Blumberg EA et al. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation 90(12), 1427-1431 (2010).
74. Humar A, Peeters P, Abramowicz D et al. Response to questions regarding the design and results of the IMPACT trial. Am. J. Transplant. 11(1), 177-178 (2011).
75. Kalil AC, Sun J, Florescu DF. IMPACT trial results should not change current standard of care of 100 days for cytomegalovirus prophylaxis. Am. J. Transplant. 11(1), 18-21 (2011).
76. Luan FL, Kommareddi M, Ojo AO. Universal prophylaxis is cost effective in cytomegalovirus serology-positive kidney transplant patients. Transplantation 91(2), 237-244 (2011).
77. Blumberg EA, Hauser IA, Stanisic S et al. Prolonged prophylaxis with valganciclovir is cost effective in reducing posttransplant cytomegalovirus disease within the United States. Transplantation 90(12), 1420-1426 (2010).
78. Asberg A, Humar A, Rollag H et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant. 7(9), 2106-2113 (2007).
79. Lamoth F, Manuel O, Venetz JP, Faouzi M, Meylan P, Pascual M. What is the impact of late-onset cytomegalovirus disease after valganciclovir prophylaxis in kidney transplantation? Transplantation 86(9), 1323-1324 (2008).
80. Arthurs SK, Eid AJ, Pedersen RA et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin. Infect. Dis. 46(6), 840-846 (2008).
81. Chamberlain CE, Penzak SR, Alfaro RM et al. Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients. Am. J. Transplant. 8(6), 1297-1302 (2008).
82. Manuel O, Pascual M, Perrottet N et al. Ganciclovir exposure under a 450 mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplantation: a prospective study. Clin. Transplant. 24(6), 794-800 (2010).
83. Kalil AC, Mindru C, Florescu DF. Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis. Clin. Infect. Dis. 52(3), 313-321 (2011).
84. Pescovitz MD. Is low-dose valganciclovir the same as appropriate-dose valganciclovir? Transplantation 84(1), 126-127 (2007).
85. Boivin G, Goyette N, Gilbert C et al. Absence of cytomegalovirus- resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J. Infect. Dis. 189(9), 1615-1618 (2004).
86. Boivin G, Goyette N, Gilbert C, Humar A, Covington E. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl. Infect. Dis. 7(3-4), 166-170 (2005).
87. Hantz S, Garnier-Geoffroy F, Mazeron MC et al. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J. Antimicrob. Chemother. 65(12), 2628-2640 (2010).
88. Toussaint ND, Tan MB, Nicholls K, Walker RG, Cohney SJ. Low-dose valaciclovir and cytomegalovirus immunoglobulin to prevent cytomegalovirus disease in high-risk renal transplant recipients. Nephrology 16(1), 113-117 (2011).
89. San JR, Yebra M, Lumbreras C et al. A new strategy of delayed long-term prophylaxis could prevent cytomegalovirus disease in (D+/R-) solid organ transplant recipients. Clin. Transplant. 23(5), 666-671 (2009).
90. Boillat Blanco N, Pascual M, Venetz JP, Nseir G, Meylan PR, Manuel O. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients. Transplantation 91(2), 251-255 (2011).
91. Danziger-Isakov L, Heeger PS. Clinical utility of measuring T-cell immunity to CMV in transplant recipients. Am. J. Transplant. 9(5), 987-988 (2009).
92. Egli A, Binet I, Binggeli S et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J. Transl. Med. 6, 29 (2008).
93. Gratama JW, Boeckh M, Nakamura R et al. Immune monitoring with iTAg MHC tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood 116(10), 1655-1662 (2010).
94. Mattes FM, Vargas A, Kopycinski J et al. Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation. Am. J. Transplant. 8(5), 990-999 (2008).
95. Giulieri S, Manuel O. QuantiFERON®- CMV assay for the assessment of cytomegalovirus cell-mediated immunity. Expert Rev. Mol. Diagn. 11(1), 17-25 (2011).
96. Walker S, Fazou C, Crough T et al. Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV. Transpl. Infect. Dis. 9(2), 165-170 (2007).
97. Kumar D, Chernenko S, Moussa G et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am. J. Transplant. 9(5), 1214-1222 (2009).
98. Palmer SM, Limaye AP, Banks M et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann. Intern. Med. 152(12), 761-769 (2010).
99. Perrottet N, Robatel C, Meylan P et al. Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients. J. Antimicrob. Chemother. 61(6), 1332-1335 (2008).
100. Kaul DR, Stoelben S, Cober E et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am. J. Transplant. 11(5), 1079-1084 (2011).
101. Griffiths PD, Stanton A, McCarrell E et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a Phase 2 randomised placebo-controlled trial. Lancet 377(9773), 1256-1263 (2011).